GSK resolves FCPA case with US$20 million SEC settlement and DOJ declination
GlaxoSmithKline, one of the larger companies to be ensnared in a seven-year-old foreign bribery sweep of the pharmaceutical industry by US authorities, announced today that it had resolved FCPA allegations at its China-based subsidiaries by paying a US$20 million civil fine to the Securities and Exchange Commission.
To read more
Subscribe to Global Investigations Review
Subscribe and start reading now
Global Investigations Review (GIR) is the hub for global coverage of corporate investigations and their aftermath. Keep up to date with significant developments in the corporate investigations world.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10